



Chronic kidney disease Queensland CKD.QLD registry study and data linkage

<u>V DIWAN</u>^{1,2} and WE HOY^{1,2} and on behalf of the CKD.QLD COLLABORATIVE ¹ NHMRC CKD.CRE and CKD.QLD, Brisbane, Queensland ² Faculty of Medicine, University of Queensland, Brisbane,

Queensland

Nov 16th, 2023



Queensland Government





Why study chronic kidney disease?

- Background
 - In 2017-18, 237,800 Australians, or 1% of the population, had kidney disease
 - In 2017, 13% of all deaths were certified where kidney disease was being a contributory factor
 - Hospitalisations for CKD as the principal diagnosis (excluding dialysis) have more than doubled between 2000–01 and 2020–21 from 24,200 to 58,200.
 - The age-standardised hospitalisation rate for CKD as a principal diagnosis rose by 64% between 2000–01 and 2020–21
 - It is essential to understand CKD in all its dimensions to predict its course, better manage the huge burden of premature deaths and delay the progression to ESKD





CKD.QLD Registry Study

- A multidisciplinary research and practice collaborative network embracing most of the renal units in the public health system in Queensland, under the jurisdiction of Queensland Health.
- concept developed in late 2009
- first patient enrolment in May 2011 with informed consent

www.ckdqld.org





CKD.QLD: Sites in Queensland

CKDLD

Queensland population:

- 5 million
- Multi-ethnic
- Spread across metropolitan, regional, rural and remote/very remote





CKD.QLD: Mission and research streams



Entity

• The only CRE focused on CKD in Australia.

Mission

 To advance knowledge about CKD and its management across the health care spectrum, in order to improve outcomes, study the progression of CKD and find ways to delay the progression towards ESKD

Research streams

- CKD surveillance
- Practice improvement
- Biomarker research
- Health services utilization among CKD patients







Evaluation of health services utilisation, costs and outcomes of patients with chronic kidney disease, who are enrolled in the CKD.QLD Registry

How we do this:



OF QUEENSLAND The data linkage framework of the sub-study of CKD.QLD Registry









F1000 Research

F1000Research 2021, 10:1107 Last updated: 07 SEP 2023



DATA NOTE

The CKD.QLD data linkage framework: chronic kidney disease

and health services utilisation in Queensland, Australia

Jianzhen Zhang ^{1,2}, Zaimin Wang^{1,2}, Anne Cameron^{1,2}, P Marcin Sowa^{2,3}, Vishal Diwan^{1,2}, Sree Krishna Venuthurupalli^{2,4}, Helen G. Healy^{2,5}, Luke B Connelly ^{2,3,6}, Wendy E Hoy^{1,2}

Implications of the linkage project:

1. Access to all hospitalisations, not limited to renal admissions, and across all disciplines

- - Profile a "bigger picture" of health service utilisations
 - valuation of more in-depth longitudinal analyses and provide evidence base
- 2. Key outcomes of the Registry have informed, and are planned to continue to inform
- - CKD health practitioners
 - Queensland Health
- - National groups: eg. the Australian Institute of Health and Welfare (AIHW)
- CKD patients





The findings



Persons with CKD were enrolled in the CKD.QLD Registry and followed until they started kidney replacement therapy (KRT), died with kidney failure without KRT, idea of other causes, or until a censor date of June 2020.



Queensland, Australia



Retrospective observational cohort study, 2011 - 2020



7,595 patients with CKD 12 public renal clinics



Association of clinical features with hospitalization, LOS, cost

LOS = length of stay, AUD = Australian dollars

59,794 hospital admissions

89% of patients admitted at least once Cost per person year: \$9525 AUD (>2x national average) Admissions per person year: 1.7 admissions (10x national average)

	Admissions	Cost		
1-day admissions	~60%	15%		
> 1-day admissions	40% 🖤	85%		
Emergency admissions	~40%	~48%		
Readmission within 30-days	-44%	47.5%		
Not related to CKD diagnosis	-89%	91%		
Top > 1-day admissions:	Top 1-day	Top 1-day admissions:		
🍇 Cardiovascular	Neoplasms (chemotherapy)			
Respiratory	é Anem	ia		
CKD-related	CKD-r	elated		

SY8



Pattern of hospital admissions and costs





Original Research

Hospitalizations Among Adults With CKD in Public Renal Specialty Practices: A Retrospective Study From Queensland, Australia

Vishal Diwan, Wendy E. Hoy, Zaimin Wang, Jianzhen Zhang, PhD, Anne Cameron, RN, Sree K. Venuthurupalli, Robert G. Fassett, Samuel Chan, Helen G. Healy, Ken-Soon Tan, Richard Baer, Andrew J. Mallett, Nicholas Gray, Murty Mantha, Roy Cherian, Clyson Mutatiri, Krishan Madhan, George Kan, Geoffrey Mitchell, Shahadat Hossain, Danielle Wu, Thin Han, Adrian Kark, Thomas Titus, Dwarakanatan Ranganathan, Ann Bonner, and Sridevi Govindarajulu, on behalf of the NHMRC CKD.CRE and the CKD.QLD Collaborative



Kidney Medicine







Further evaluation



Comparison: Indigenous vs Non-Indigenous

Indigenous patients, per person year of follow up, had



Indigenous patients, per 100-person year, had higher incidence rate





Comparison: Indigenous vs Non-Indigenous



	Per 100 person years				
	Admissions		Cost		
	Indigenous	Non- Indigenous	Indigenous	Non- Indigenous	
All admissions	181.7	165.9	1,260,070	931,648	
>1-day admissions	84.7	66.1	1,082,421	787,857	
ED admissions	90.7	64.4	681,677	434,370	
All readmissions	77.9	72.5	669,283	443,357	
>1-day readmissions	39.2	29.7	607,313	389,435	





Hospital admissions: principal diagnosis

	Non-Indigenous		Indigenous		
ICD chapters	Non- Indigenous	% by total admissions among non- Indigenous	Indigenous	% by total admissions among Indigenous	P values
9: Circulatory system	4,813	12.7	364	13.6	0.181
L8: Abnormal clinical/laboratory findings	3,238	8.5	272	10.1	0.005
L4: Kidney & genitourinary system	2,864	7.6	249	9.3	0.002
LO: Respiratory system	2,291	6.0	244	9.1	0.000
21: Factors influencing health status	4,966	13.1	235	8.7	0.000
1: Endocrine, nutritional & metabolic	2,039	5.4	223	8.3	0.000





Incidence rate of end points by Indigenous status

	Indigenous	Non-Indigenous	Ρ
All ESKD	10.9 (9.2-12.5)	7.8 (7.4-8.2)	P<0000, RR, 1.39
KRT	4.9 (4.1-5.9)	2.2 (2.0-2.3)	P<0.0001, RR 2.24
Renal death	3.0 (2.4-3.8)	3.1 (2.9-3.3)	P=0.782, RR 0.967
Nonrenal death	1.73 (1.3-2.3)	2.66 (2.48-2,83)	P=0.0065, RR 0.65







Equity and Chronic Kidney Disease (CKD) in Indigenous adults in Public Renal Specialty Services in the Australian state of Queensland, a CKD.QLD registry study.

Diabetes minimises female protection among Indigenous Australian females against ESKD: A CKD.QLD registry study.

List of Authors and affiliations

Vishal Diwan^{1,2} M Pharm PhD, Wendy E Hoy ^{1,2} MBBS FRACP, Zaimin Wang^{1,2} PhD, Jianzhen Zhang ^{1,2} PhD, Anne Cameron^{1,2} RN, Sree K Venuthurupalli^{1,2,3} MBBS MD PhD FRACP, Robert G Fassett ^{22, 23} MBBS FRACP PhD, Samuel Chan ² MBBS FRACP, Helen G Healy^{1,2,4} MBBS PhD, Ken-Soon Tan⁵ MD, Richard Baer MBBS MPH^{5,6}, Andrew J Mallett ^{2,7,8} MBBS PhD, Nicholas Gray ⁹ MD, Murty Mantha⁶ MD, Roy Cherian ¹⁰ MD, Clyson Mutatiri ¹¹ MD, Krishan Madhan ^{12,13} MD, George Kan ⁸ MD, Geoffrey Mitchell ² PhD, Shahadat Hossain ¹⁴ MD, Danielle Wu ¹⁵MD, Thin Han ^{16,17} MD, Adrian Kark ⁴ MD, Sonya Coleman⁴ NP, Thomas Titus ¹⁸ MD, Dwarakanatan Ranganathan ^{4,19} MD, Ann Bonner^{1,4, 20} RN PhD, Sridevi Govindarajulu ²¹ MD Tracey Johnson²⁴, Suzanne Williams²⁴, on behalf of the NHMRC CKD.CRE and the CKD.QLD Collaborative.



Future perspectives:

Post marketing surveillance: Newer classes of medicines for control of weight, diabetes, and cardiovascular and renal protection:-

- Sodium-glucose Cotransporter-2 (SGLT2) inhibitors
- Glucagon-Like Peptide-1 (GLP-1) inhibitors
- newer mineralocorticoid inhibitors
- Dipeptidyl peptidase-4 (DPP-4) inhibitors

Comparison of hospitalisation before and after KRT:

- Changes in pattern (1-day, >1-day, readmissions, ED admissions)
- Changes in reason of hospitalisations



Acknowledgements



Patients who consented and enrolled with CKD.QLD registry

Statistical Analysis and Linkage Unit

Queensland public renal services staff

Queensland Health data custodians

NHMRC

